Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a biotechnology company focused on developing novel cancer treatments, stands at ...

Akero Therapeutics’ impressive performance in both stock price and clinical trials has made it a stock to watch in 2025. With a promising treatment on the horizon and significant gains to show for it, ...

In a challenging market environment, Centrexion Therapeutics Corp stock has touched a 52-week low, with shares falling to $0.9. According to InvestingPro data, the stock shows significant volatility ...

These two Fate series are a great way to pass the time until an official release date drops for the first season of ...

With every new year comes reflection and resolutions. But as we go to press well into January, it is worth a reminder that studies show nearly 90% ...

Sage Therapeutics has a unique approach to targeting GABA, which allows it to target CNS disorders. Read why I think SAGE ...

The firm will evaluate its CLDN6- and CD3 T-cell-engaging bispecific antibody in advanced or metastatic ovarian, endometrial, and testicular cancers.

Research presented at SABCS 2024 provided new insights that may influence the management of early and advanced breast cancer.

Context Therapeutics (CNTX) announced that the first patient has been dosed in its Phase 1 clinical trial evaluating CTIM-76, a Claudin 6, or ...

CTIM-76 Phase 1 trial focused on CLDN6-positive gynecologic and testicular cancers Trial marks key milestone in driving pipeline progress PHILADELPHIA, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Context ...

PHILADELPHIA - Context Therapeutics Inc. (NASDAQ:CNTX), a company specializing in T cell engaging therapies for solid tumors, announced today the appointment of Andy Pasternak as its new Chairman of ...